Trump's push for drug self-reliance puts pressure on Indian pharma

Indian pharmaceutical stocks are reeling from policy jitters after US President Donald Trump signed an executive order on Monday aimed at ramping up domestic drug manufacturing, a move that threatens to undercut India's highly export-driven pharma sector. Stocks such as Aurobindo Pharma, and Lupin (with heavy revenue dependence on the US) have shown signs of weakness.